Elisabeth Hessmann

Elisabeth Hessmann

Robert Koch Str. 40
Goettingen, NI 37075, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Journal: Nature medicine

Published: January 29, 2026

Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma.

Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma.

Journal: Molecular cancer

Published: November 10, 2025

Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.

Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.

Journal: Cancer research communications

Published: October 27, 2025

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

Journal: Scientific reports

Published: August 08, 2025

TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.

TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.

Journal: Science advances

Published: July 04, 2025

GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.

GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.

Journal: Gut

Published: July 03, 2025

The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.

The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.

Journal: MedComm

Published: June 25, 2025

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.

Journal: Cell death & disease

Published: April 30, 2025

Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer.

Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer.

Journal: Gastroenterology

Published: February 19, 2025

Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer.

Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer.

Journal: Gut

Published: November 18, 2024

A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys.

A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient Journeys.

Journal: Studies in health technology and informatics

Published: September 05, 2024

Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Journal: Nature medicine

Published: May 30, 2024

Showing 1-12 of 62

Last Updated: 09/26/2026